Department of Surgical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009, Marseille, France.
Department of Surgical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, 27 Boulevard Leï Roure, CS 30059, 13273, Marseille Cedex 09, France.
Langenbecks Arch Surg. 2022 May;407(3):1065-1071. doi: 10.1007/s00423-021-02334-2. Epub 2021 Oct 27.
Positive para-aortic lymph nodes (PALN) (station 16) are commonly detected in the final pathologic examination (ranging from 15 to 26%) among patients who undergo upfront pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma. However, after neoadjuvant treatment (NAT) the role of positive PALN as a watershed for surgical resection remains unclear. We aimed to determine the incidence of intraoperative detection of PALN after NAT with FOLFIRINOX for pancreatic head adenocarcinoma and its impact on survival, as our policy was to not resect the tumor in such situations.
From January 2014 to December 2020, 136 patients with non-metastatic cancer who received neoadjuvant FOLFIRINOX and underwent explorative laparotomy were included.
Intraoperative positive PALN were observed in 7 patients (5%). Patients had resectable (n = 5) or locally advanced (n = 2) disease at the time of surgery, but none of them underwent surgical resection. Positive PALN were significantly associated with a lower median number of FOLFIRINOX cycles (4 vs. 6, P = 0.05). There was no significant difference in overall survival between patients with positive loco-regional lymph nodes after resection and patients with non-resection owing to positive PALN (22 versus 16 months, P = 0.16), Overall survival with positive PALN, carcinomatosis, and liver metastasis was 16, 14, and 10 months, respectively (P > 0.05).
Our results suggest that NAT may lower PALN involvement. We have modified our policy, positive PALN after NAT are no longer a contraindication to resection, rather a holistic picture of the disease guides management.
在接受胰十二指肠切除术治疗可切除的胰腺导管腺癌的患者中,在最终病理检查中常发现阳性腹膜后淋巴结(PALN)(站 16)(范围为 15%至 26%)。然而,在新辅助治疗(NAT)后,阳性 PALN 作为手术切除的分水岭的作用仍不清楚。我们旨在确定接受新辅助 FOLFIRINOX 治疗胰头腺癌后术中检测 PALN 的发生率及其对生存的影响,因为我们的政策是在这种情况下不切除肿瘤。
从 2014 年 1 月至 2020 年 12 月,纳入 136 例接受新辅助 FOLFIRINOX 治疗并接受探查性剖腹手术的非转移性癌症患者。
术中观察到 7 例(5%)阳性 PALN。患者在手术时具有可切除(n=5)或局部晚期(n=2)疾病,但均未进行手术切除。阳性 PALN 与中位 FOLFIRINOX 周期数较低显著相关(4 与 6,P=0.05)。在接受切除术的局部区域淋巴结阳性患者和因 PALN 阳性而未接受切除术的患者之间,总生存率无显著差异(22 与 16 个月,P=0.16)。阳性 PALN、癌转移和肝转移的总生存率分别为 16、14 和 10 个月(P>0.05)。
我们的结果表明,NAT 可能降低 PALN 的受累程度。我们已经修改了我们的政策,NAT 后阳性 PALN 不再是切除的禁忌症,而是疾病的整体情况指导管理。